The plasma derivatives manufacturer Grifols has announced today to the CNMV that the obtaining of plasma, from which it makes its products, "has recovered from the lows reached during the pandemic" and since May it has already exceeded the average monthly volume of 2019.
The Catalan group has explained in information to the regulator that "in turn, the increase in collected plasma has driven an increase in sales", so that the company expects revenues in the second half of the year to grow in double digits compared to the second half of 2021.
In July, the company said its revenue had risen 11% in the first half of the year thanks to a 22% increase in plasma collection, and that it expected the trend to continue in the second half of the year.
The note indicates that the Grifols board sends the communication "in a context of considerable geopolitical uncertainty and market volatility" that has caused the share price to fall by 54% since last year.
The firm was especially penalized on the stock market last week due to the downgrade of the rating agency Standard
Two other rating agencies, Moody's and Fitch, have instead maintained the company's credit ratings since, according to Grifols, they value the measures that are being adopted to improve their results, backed by the recovery of plasma donations and the improvement in Free cash flow.
In the communication sent today to the CNMV, the Grifols board of directors assures that it is evaluating "several strategic alternatives" to reduce its indebtedness, while improving cash flow. The company run by Victor and Raimon Grifols, he explained, ended August with unused cash and financial lines totaling more than 1.3 billion euros.
The council adds that they are working to reduce costs, improve operating efficiencies and recover inventory levels and explains that it will republish its results on a quarterly basis starting next year.
